Hip fracture
Conditions
Interventions
Daily treatment group:Elcitonin injection 40IU, administered intramuscularly daily, until 2 weeks after the operation
Weekly treatment group:Elcitonin injection 20IU, administered intramuscularly once a week until 2 weeks after the operation
Control group:Conventional treatment (without calcitonin drugs), but standard perioperative bone health management is provided (including calcium and vitamin D supplementation, rehabilitation guidance
Sponsors
Peking Union Medical College Hospital
Eligibility
Sex/Gender
All
Age
50 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age over 50; 2. Hip fracture; 3. Braking is required for a certain period of time; 4. Newly diagnosed patients who have not received calcitonin treatment; 5. The liver, kidneys and other organ functions are good, and the patient can tolerate surgery and drug treatment. 6. Patients and their families can understand the research protocol and voluntarily participate in this study, and voluntarily sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Hypocalcemia 2. Those who are allergic to or intolerant to elcitonin drugs; 3. Patients with allergic constitutions who are prone to rashes (erythema, rubella), etc. 4. Patients who have received calcitonin preparations or the bone resorption inhibitor bisphosphonate within the past three months; 5. Patients who concurrently use cardiac glycosides or calcium channel blockers during the treatment period; 6. Patients with bronchial asthma or a history of the disease; 7. Diseases or factors with abnormal clinical manifestations that need to be ruled out, including but not limited to diseases of the nervous system, cardiovascular system, kidneys, liver, gastrointestinal tract, respiratory system, metabolism, bones and other systems; 8. Participated in other clinical researchers in the past three months; 9. Have any other circumstances that the researcher deems unsuitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Bone mineral density (BMD); | — |
Secondary
| Measure | Time frame |
|---|---|
| Bone turnover marker;Blood calcium level;24-hour urinary calcium level;Visual analogue scale,VAS;Sarcopenia score;The patients safety assessment ; | — |
Countries
China
Contacts
Public ContactJia Zhang
Peking Union Medical College Hospital
Outcome results
None listed